TARSUS PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
TARSUS PHARMACEUTICALS, INC. (TARS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 491.64 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-06
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 28.58K shares, a 31.21% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 463.06K shares, a 1.37% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 26.27K shares, a 61.11% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 58.59K shares, a 162.90% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 583.24K shares, a 25.61% decline from fiscal 2024.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 784.04K shares, a 33.17% decline from fiscal 2023.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 1.17M shares, a 4.39% decline from fiscal 2022.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 1.23M shares, a 22.04% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 28.58K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 491.64K shares 10-Q · filed 2026-08-06 | 517.91K shares derived: sum of 3 quarters · filed 2026-08-06 | 576.51K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 463.06K shares 10-Q · filed 2026-05-06 | 489.33K shares derived: sum of 2 quarters · filed 2026-05-06 | 547.92K shares derived: sum of 3 quarters · filed 2026-05-06 | 589.47K shares derived: sum of 4 quarters · filed 2026-05-06 |
| 2025-12-31 | 26.27K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | 84.86K shares derived: sum of 2 quarters · filed 2026-02-23 | 126.41K shares derived: sum of 3 quarters · filed 2026-02-23 | 583.24K shares 10-K · filed 2026-02-23 |
| 2025-09-30 | 58.59K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | 100.14K shares derived: sum of 2 quarters · filed 2025-11-04 | 556.97K shares 10-Q · filed 2025-11-04 | 624.52K shares derived: sum of 4 quarters · filed 2025-11-04 |
| 2025-06-30 | 41.55K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | 498.37K shares 10-Q · filed 2025-08-06 | 565.92K shares derived: sum of 3 quarters · filed 2025-08-06 | 588.21K shares derived: sum of 4 quarters · filed 2025-08-06 |
| 2025-03-31 | 456.82K shares 10-Q · filed 2025-05-01 | 524.38K shares derived: sum of 2 quarters · filed 2025-05-01 | 546.66K shares derived: sum of 3 quarters · filed 2025-05-01 | 606.97K shares derived: sum of 4 quarters · filed 2025-05-01 |
| 2024-12-31 | 67.55K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | 89.84K shares derived: sum of 2 quarters · filed 2025-02-25 | 150.15K shares derived: sum of 3 quarters · filed 2025-02-25 | 784.04K shares 10-K · filed 2025-02-25 |
| 2024-09-30 | 22.29K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 82.60K shares derived: sum of 2 quarters · filed 2024-11-13 | 716.48K shares 10-Q · filed 2024-11-13 | 747.92K shares derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | 60.31K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 694.20K shares 10-Q · filed 2024-08-08 | 725.64K shares derived: sum of 3 quarters · filed 2024-08-08 | 855.90K shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 633.89K shares 10-Q · filed 2024-05-08 | 665.33K shares derived: sum of 2 quarters · filed 2024-05-08 | 795.59K shares derived: sum of 3 quarters · filed 2024-05-08 | 1.08M shares derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-12-31 | 31.44K shares derived: 10-K 12 month − 3 quarters · filed 2024-02-27 | 161.71K shares derived: sum of 2 quarters · filed 2024-02-27 | 445.07K shares derived: sum of 3 quarters · filed 2024-02-27 | 1.17M shares 10-K · filed 2024-02-27 |
| 2023-09-30 | 130.27K shares 10-Q · filed 2023-11-09 | 413.63K shares derived: sum of 2 quarters · filed 2023-11-09 | 1.14M shares derived: sum of 3 quarters · filed 2023-11-09 | |
| 2023-06-30 | 283.37K shares 10-Q · filed 2023-11-09 | 1.01M shares derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2023-03-31 | 728.17K shares 10-Q · filed 2023-11-09 | |||
| 2022-12-31 | 1.23M shares 10-K · filed 2024-02-27 | |||
| 2021-12-31 | 1.01M shares 10-K · filed 2023-03-17 | |||
| 2020-12-31 | 1.74M shares 10-K · filed 2022-03-14 | |||
| 2019-12-31 | 32.79K shares 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |